Department of Clinical Sciences Lund, Oncology and Therapeutic Pathology, Lund University, Lund, Sweden.
Department of Clinical Sciences Lund, Oncology, Lund University, Lund, Sweden.
J Innate Immun. 2022;14(6):615-628. doi: 10.1159/000524434. Epub 2022 May 3.
Tumor-associated macrophages (TAMs) have emerged as key players in tumor immunology but demonstrate a continuum of functional states being either tumor suppressive or promoting. Moreover, chemotherapeutic agents have been shown to alter the tumor microenvironment. Perioperative chemotherapy is a standard treatment option for resectable esophageal and gastric (EG) adenocarcinoma. The aim of this study was to investigate the influence of neoadjuvant chemotherapy (NAC) on TAMs to improve the prognostication and treatment course for these patients. The study cohort comprised 148 patients, all of whom were diagnosed with resectable EG adenocarcinoma and treated with NAC. Immunohistochemistry was applied to assess the total infiltration and infiltration into tumor nests (TN) of CD68+/CD163-, CD68+/CD163+, and MARCO+ TAMs, on paired biopsies from primary tumors (PT) pre-NAC, and resected PT and lymph node metastases post-NAC. In pre-NAC specimens, high CD68+/CD163+ infiltration into TN was an unfavorable prognostic factor. No association was found between TAM density in PT pre-NAC and histopathological regression. The density of CD68+/CD163+ TAMs was increased in PT post-NAC, while the density of MARCO+ TAMs was decreased. CD68+/CD163- TAM density was not altered. In post-NAC specimens, higher total as well as TN infiltration of CD68+/CD163- TAMs were adverse prognostic factors. In conclusion, these results suggest that NAC may alter certain TAM subsets in EG adenocarcinoma, along with their functional properties and thus their prognostic value.
肿瘤相关巨噬细胞(TAMs)已成为肿瘤免疫学的关键参与者,但表现出连续的功能状态,既有肿瘤抑制作用,也有促进作用。此外,化疗药物已被证明可以改变肿瘤微环境。围手术期化疗是可切除食管和胃(EG)腺癌的标准治疗选择。本研究旨在探讨新辅助化疗(NAC)对 TAMs 的影响,以改善这些患者的预后和治疗过程。研究队列包括 148 名被诊断为可切除 EG 腺癌并接受 NAC 治疗的患者。应用免疫组织化学评估 CD68+/CD163-、CD68+/CD163+和 MARCO+TAMs 在原发性肿瘤(PT)术前、术后 NAC 时 PT 和淋巴结转移的总浸润和浸润肿瘤巢(TN)的情况。在术前标本中,TN 中高 CD68+/CD163+浸润是不利的预后因素。PT 术前 NAC 时 TAM 密度与组织病理学缓解之间没有关联。PT 术后 CD68+/CD163+TAMs 的密度增加,而 MARCO+TAMs 的密度降低。CD68+/CD163-TAM 密度没有改变。在术后标本中,较高的总浸润和 TN 浸润 CD68+/CD163- TAMs 是不良预后因素。总之,这些结果表明,NAC 可能改变 EG 腺癌中某些 TAM 亚群及其功能特性,从而影响其预后价值。